Calton & Associates’s Ingevity NGVT Stock Holding History

Calton & Associates’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-329	Closed	-$24K	–	951
2017 Q4	$24K	Buy	+329	New	+$23.7K	0.01%	855

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIC

Chilton Investment Company Stamford, Connecticut $4.26B AUM 1.32% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

CCM

Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Calton & Associates's NGVT Position: Q1 2018 in Review

Calton & Associates sold out of Ingevity (NGVT) in Q1 2018, closing a stake of 329 shares — an estimated $24K sold.

Calton & Associates first reported a position in NGVT in Q4 2017 and held it in 1 quarter. The position peaked at $24K in Q4 2017. 312 funds tracked by Wall St. Rank hold NGVT as of Q1 2018.

Calton & Associates reported no remaining Ingevity position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 329 Ingevity shares in Q1 2018, an estimated $24K.
Calton & Associates first reported a position in Ingevity in Q4 2017 and held it in 1 quarter.
Calton & Associates's Ingevity position peaked at $24K in Q4 2017.
312 funds tracked by Wall St. Rank held Ingevity as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.